Breast cancer test maker Agendia has released new data suggesting its MammaPrint genomic diagnostic spots breast cancer patients with ultra-low risk of recurrence, who could skip chemo and are likely to keep cancer at bay for at least 20 years. This information, culled from an analysis of 70 different genes, could help oncologists tailor treatment plans for certain early-stage breast cancer cases,…
![](https://femtechinsider.com/wp-content/uploads/2021/06/breast-cancer-femtech-1000x658.jpg)